Richard Giroux, the Chief Financial Officer and Chief Operating Officer of MeiraGTx Holdings plc, has sold 56,000 shares of the company on October 20, 2026. This transaction is significant as it highlights the ongoing adjustments in executive holdings within the company.
MeiraGTx Holdings plc operates in the biological products sector, focusing on innovative therapies for serious diseases. The company is listed under the Central Index Key (CIK) 0001735438, and its trading symbol is MGTX. It is categorized under the SIC code for Biological Products (No Diagnostic Substances) [2836].
According to the filing, Giroux's sale was executed as part of a Rule 10b5-1 trading plan that he adopted on November 18, 2025. The shares were sold at a weighted average price of $9.95, with individual transactions ranging from $9.5188 to $10.12. Following this sale, Giroux now holds a total of 852,530 shares of MeiraGTx.
The impact of Giroux's sale may resonate within the industry, as it reflects a trend where executives actively manage their stock portfolios. This could influence investor perceptions and market dynamics in the biological products sector.
Details regarding future transactions or further filings were not disclosed in the current filing.
In addition to the sale of shares, the filing indicates that Richard Giroux also holds 5,152 shares indirectly through his spouse, demonstrating a broader family investment in MeiraGTx Holdings plc. Furthermore, Giroux has an indirect ownership of 85,000 shares through Aigle Healthcare Partners III LLC, suggesting a diversified approach to his investment strategy.
The filing does not provide any information on Giroux's future plans regarding his holdings or any potential upcoming transactions. Additionally, there are no details regarding the company's performance or strategic initiatives that may have influenced Giroux's decision to sell shares at this time.